We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Abcam

Abcam is an innovator in reagents and tools, and provides tools and scientific support to the research and clinical c... read more Featured Products: More products

Download Mobile App




Danaher Acquires UK Biotech Company Abcam

By LabMedica International staff writers
Posted on 30 Aug 2023
Print article
Image: Abcam is expected to brand within Danaher’s Life Sciences segment (Photo courtesy of Abcam)
Image: Abcam is expected to brand within Danaher’s Life Sciences segment (Photo courtesy of Abcam)

Danaher Corporation (Waltham, MA, USA) has entered into a definitive agreement to acquire all of the outstanding shares of Abcam plc (Cambridge, UK) for USD 24 per share in cash. The transaction was unanimously approved and recommended by the Abcam board of directors and unanimously approved by the Danaher board of directors.

Founded in 1998, Abcam offers the scientific community a wide range of extensively validated antibodies, reagents, biomarkers, and assays. These resources serve to target key biological pathways critical for the advancement of drug discovery, life sciences research, and diagnostics. The company's technologies find application among approximately 750,000 researchers. Under the planned arrangement, Abcam is poised to continue operating as an independent entity and brand within Danaher's Life Sciences sector. The acquisition of Abcam reflects Danaher's strategy to contribute towards mapping complex diseases and accelerating the process of drug discovery.

“Our strategy has transformed Abcam to become a scale innovator and important catalyst in the global life science community,” said Alan Hirzel, Chief Executive Officer of Abcam. “Danaher shares our passion to help life science researchers achieve their mission faster and their operating company model allows us to continue to pursue our strategy, while harnessing the power of the Danaher Business System to ensure we remain the partner of choice for our customers.”

“We couldn’t be more excited to have Abcam join Danaher,” added Rainer M. Blair, President and Chief Executive Officer, Danaher. “Abcam’s long track record of innovation, outstanding product quality and breadth of antibody portfolio positions them as a key partner for the scientific community. We look forward to welcoming Abcam’s innovative and talented team to Danaher as we continue to help our customers solve some of the world’s biggest healthcare challenges."

Related Links:
Danaher Corporation 
Abcam plc

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Magnetic Bead Separation Modules
MAG and HEATMAG

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A blood test could predict lung cancer risk more accurately and reduce the number of required scans (Photo courtesy of 123RF)

Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans

Lung cancer is extremely hard to detect early due to the limitations of current screening technologies, which are costly, sometimes inaccurate, and less commonly endorsed by healthcare professionals compared... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Pathology

view channel
Image: Comparison of traditional histopathology imaging vs. PARS raw data (Photo courtesy of University of Waterloo)

AI-Powered Digital Imaging System to Revolutionize Cancer Diagnosis

The process of biopsy is important for confirming the presence of cancer. In the conventional histopathology technique, tissue is excised, sliced, stained, mounted on slides, and examined under a microscope... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.